AB0960 EFFECT OF BODY MASS INDEX ON TREATMENT RESPONSE OF BIOLOGIC-/TARGETED SYNTHETIC DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS

Background Overweight and/or obese patients with inflammatory arthritis (IA) have higher disease activity and lower chances of achieving as well maintaining the treatment targets. Obesity also appears to negatively affect response tumor necrosis factor (TNF) inhibitors in IA. The efficacy other biologic (b) targeted-synthetic (ts) DMARDs overweight/obese IA, including rheumatoid –RA, psoriatic –PsA, axial spondyloarthritis –AxSpA, is unclear. Objectives To conduct a systematic literature review (SLR) explore effect weight/body-mass-index (BMI) on all b-/ts-DMARDs approved for RA, PsA AxSpA. Methods For this PROSPERO-registered SLR, we searched PubMed, Scopus Cohrane-Library up June 21 st 2022. PICO-format was follows: Population: adults or AxSpA low/normal weight/BMI; Intervention: b-/ts-DMARDs; Comparator: high/abnormal Outcome: any outcome used assessment (e.g DAS28, ACR20, drug-survival). search query included following keywords article’s title abstract: (“psoriatic arthritis” OR “rheumatoid “inflammatory “ankylosing spondylitis” “axial spondyloarthritis” “non-radiographic spondyloarthritis”) AND (DMARDs bDMARDs tsDMARDs tofacitinib upadacitinib baricitinib filgotinib apremilast anti-TNF etanercept infliximab adalimumab golimumab certolizumab abatacept rituximab tocilizumab anti-IL-6 anti-IL-17 anti-IL-23 anti-IL-12/23 ustekinumab guselkumab risankizumab secukinumab ixekizumab “janus kinase inhibitors” “JAK inhibitor”) (“body mass index” BMI obes* weight). Clinical-trials observational studies were included. screening selection process conducted independently by two reviewers. Risk bias (ROB) assessed using RoB2-Cochrane tool Newcastle-Ottawa scale randomized non-randomized studies, respectively. Results Out 996 references, 192 full-text articles reviewed 75 eventually fulfilled inclusion criteria (of which 10 retrieved through manual-search). Number most medium RoB, was: 34 TNF-inhibitors, 4 IL-12/23 inhibitors, 1 IL-23 inhibitor, 7 IL-17 18 tocilizumab, 8 abatacept, 3 5 JAK-inhibitors. TNF-inhibitors found be affected forms IA being similar across various TNF-inhibitors. In contrast, favorable results do not appear influenced increased Similar evidence exists while no conclusion can drawn rituximab. More data are needed JAK-inhibitors, although weight/BMI does seem significant so far ( Figure-1 ). Conclusion Weight/BMI should considered treatment-plan its more pronounced compared b-/ts-DMARDs. Figure -1 b- ts-DMARDs Red color: negative effect, green yellow limited data, green/yellow knitting: possibly but white: applicable. Acknowledgements None. Disclosure Interests Chrysoula G. Gialouri: None declared, Maria Pappa: Gerasimos Evangelatos: Elena Nikiphorou Speakers bureau: honoraria/speaker fees from Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, Lilly, Fresenius, Grant/research support from: research grants Pfizer George E. Fragoulis has received Genesis, Novartis, UCB, Janssen, Amgen Aenorasis.